Aurinia Historical Balance Sheet

AUPH Stock

USD 8.85 0.14 1.61%

Trend analysis of Aurinia Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 102.5 M, Other Current Liabilities of 38 M or Total Current Liabilities of 81 M provides information on Aurinia Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Aurinia Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Aurinia Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Aurinia Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aurinia Pharmaceuticals is a good buy for the upcoming year.

Aurinia Pharmaceuticals Inventory

41.69 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

About Aurinia Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Aurinia Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Aurinia Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aurinia Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aurinia currently owns. An asset can also be divided into two categories, current and non-current.

Aurinia Pharmaceuticals Balance Sheet Chart

As of now, Aurinia Pharmaceuticals' Total Current Liabilities is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Total Stockholder Equity is estimated to increase to about 396.9 M, while Retained Earnings are forecasted to increase to (895.2 M).

Short Long Term Debt Total Other Current Liab Total Current Liabilities Additional Paid In Capital

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Aurinia Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aurinia Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Additional Paid In Capital

Additional Paid In Capital (or APIC) is an accounting term found on Aurinia Pharmaceuticals Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x Aurinia Pharmaceuticals Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of Aurinia Pharmaceuticals shares and does not have any impact on the value of APIC. The excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders.

Most accounts from Aurinia Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Total Current Liabilities is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Total Stockholder Equity is estimated to increase to about 396.9 M, while Retained Earnings are forecasted to increase to (895.2 M).

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	8.7M	8.1M	97.6M	102.5M
Total Assets	543.4M	470.9M	548.1M	575.5M

Short Long Term Debt Total Total Assets

Aurinia Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Current Deferred Revenue	Cash	Non Currrent Assets Other	Cash And Short Term Investments	Other Liab
Total Assets		0.62	0.91	0.89	0.99	0.65	-0.32	-0.96	0.49	0.73	0.82	0.97	0.76	0.9	0.92	0.23	0.85	0.65	0.99	0.61	-0.26	0.6	0.58	0.1	0.98	0.44
Short Long Term Debt Total	0.62		0.63	0.87	0.49	0.99	0.4	-0.68	0.28	0.98	0.85	0.6	0.95	0.84	0.47	0.27	0.94	0.99	0.51	0.99	-0.2	0.01	-0.08	-0.1	0.45	0.05
Other Current Liab	0.91	0.63		0.93	0.89	0.68	-0.03	-0.9	0.25	0.75	0.88	0.85	0.66	0.87	0.85	0.32	0.81	0.68	0.89	0.59	-0.36	0.59	0.27	0.23	0.86	0.2
Total Current Liabilities	0.89	0.87	0.93		0.82	0.89	0.13	-0.92	0.34	0.93	0.96	0.85	0.88	0.96	0.79	0.33	0.97	0.89	0.83	0.84	-0.33	0.37	0.18	0.09	0.78	0.19
Total Stockholder Equity	0.99	0.49	0.89	0.82		0.52	-0.44	-0.93	0.48	0.62	0.74	0.95	0.65	0.82	0.92	0.2	0.75	0.52	1.0	0.48	-0.24	0.68	0.66	0.13	1.0	0.47
Property Plant And Equipment Net	0.65	0.99	0.68	0.89	0.52		0.4	-0.7	0.24	0.98	0.88	0.6	0.94	0.85	0.49	0.32	0.94	1.0	0.54	0.98	-0.3	0.07	-0.08	-0.11	0.48	0.01
Net Debt	-0.32	0.4	-0.03	0.13	-0.44	0.4		0.18	-0.41	0.3	0.24	-0.35	0.12	0.03	-0.33	0.22	0.13	0.4	-0.43	0.36	-0.12	-0.51	-0.95	0.04	-0.5	-0.59
Retained Earnings	-0.96	-0.68	-0.9	-0.92	-0.93	-0.7	0.18		-0.54	-0.76	-0.87	-0.96	-0.8	-0.93	-0.94	-0.3	-0.88	-0.69	-0.94	-0.66	0.21	-0.45	-0.44	-0.19	-0.91	-0.46
Accounts Payable	0.49	0.28	0.25	0.34	0.48	0.24	-0.41	-0.54		0.27	0.3	0.65	0.48	0.51	0.57	-0.11	0.43	0.24	0.5	0.25	0.07	0.16	0.53	0.03	0.51	0.9
Non Current Assets Total	0.73	0.98	0.75	0.93	0.62	0.98	0.3	-0.76	0.27		0.88	0.69	0.93	0.88	0.55	0.28	0.96	0.98	0.63	0.96	-0.19	0.18	0.02	-0.06	0.57	0.1
Net Receivables	0.82	0.85	0.88	0.96	0.74	0.88	0.24	-0.87	0.3	0.88		0.77	0.84	0.92	0.76	0.37	0.93	0.88	0.76	0.83	-0.36	0.33	0.05	0.16	0.7	0.1
Common Stock Shares Outstanding	0.97	0.6	0.85	0.85	0.95	0.6	-0.35	-0.96	0.65	0.69	0.77		0.75	0.88	0.93	0.16	0.82	0.6	0.96	0.58	-0.16	0.49	0.59	0.15	0.95	0.59
Non Current Liabilities Total	0.76	0.95	0.66	0.88	0.65	0.94	0.12	-0.8	0.48	0.93	0.84	0.75		0.91	0.64	0.26	0.97	0.94	0.68	0.95	-0.23	0.11	0.2	-0.11	0.63	0.27
Inventory	0.9	0.84	0.87	0.96	0.82	0.85	0.03	-0.93	0.51	0.88	0.92	0.88	0.91		0.86	0.31	0.96	0.85	0.85	0.81	-0.34	0.31	0.27	0.02	0.8	0.32
Other Current Assets	0.92	0.47	0.85	0.79	0.92	0.49	-0.33	-0.94	0.57	0.55	0.76	0.93	0.64	0.86		0.29	0.73	0.49	0.94	0.45	-0.3	0.5	0.54	0.23	0.92	0.5
Other Stockholder Equity	0.23	0.27	0.32	0.33	0.2	0.32	0.22	-0.3	-0.11	0.28	0.37	0.16	0.26	0.31	0.29		0.3	0.32	0.21	0.25	-0.47	0.1	-0.13	0.0	0.18	-0.04
Total Liab	0.85	0.94	0.81	0.97	0.75	0.94	0.13	-0.88	0.43	0.96	0.93	0.82	0.97	0.96	0.73	0.3		0.94	0.77	0.93	-0.28	0.24	0.2	-0.01	0.72	0.24
Property Plant And Equipment Gross	0.65	0.99	0.68	0.89	0.52	1.0	0.4	-0.69	0.24	0.98	0.88	0.6	0.94	0.85	0.49	0.32	0.94		0.54	0.98	-0.3	0.06	-0.08	-0.11	0.48	0.01
Total Current Assets	0.99	0.51	0.89	0.83	1.0	0.54	-0.43	-0.94	0.5	0.63	0.76	0.96	0.68	0.85	0.94	0.21	0.77	0.54		0.5	-0.26	0.65	0.66	0.13	1.0	0.48
Short Term Debt	0.61	0.99	0.59	0.84	0.48	0.98	0.36	-0.66	0.25	0.96	0.83	0.58	0.95	0.81	0.45	0.25	0.93	0.98	0.5		-0.18	-0.03	-0.05	-0.12	0.44	0.02
Intangible Assets	-0.26	-0.2	-0.36	-0.33	-0.24	-0.3	-0.12	0.21	0.07	-0.19	-0.36	-0.16	-0.23	-0.34	-0.3	-0.47	-0.28	-0.3	-0.26	-0.18		-0.16	0.02	0.17	-0.24	0.2
Current Deferred Revenue	0.6	0.01	0.59	0.37	0.68	0.07	-0.51	-0.45	0.16	0.18	0.33	0.49	0.11	0.31	0.5	0.1	0.24	0.06	0.65	-0.03	-0.16		0.58	0.19	0.67	0.32
Cash	0.58	-0.08	0.27	0.18	0.66	-0.08	-0.95	-0.44	0.53	0.02	0.05	0.59	0.2	0.27	0.54	-0.13	0.2	-0.08	0.66	-0.05	0.02	0.58		-0.08	0.71	0.64
Non Currrent Assets Other	0.1	-0.1	0.23	0.09	0.13	-0.11	0.04	-0.19	0.03	-0.06	0.16	0.15	-0.11	0.02	0.23	0.0	-0.01	-0.11	0.13	-0.12	0.17	0.19	-0.08		0.12	0.16
Cash And Short Term Investments	0.98	0.45	0.86	0.78	1.0	0.48	-0.5	-0.91	0.51	0.57	0.7	0.95	0.63	0.8	0.92	0.18	0.72	0.48	1.0	0.44	-0.24	0.67	0.71	0.12		0.51
Other Liab	0.44	0.05	0.2	0.19	0.47	0.01	-0.59	-0.46	0.9	0.1	0.1	0.59	0.27	0.32	0.5	-0.04	0.24	0.01	0.48	0.02	0.2	0.32	0.64	0.16	0.51

Click cells to compare fundamentals

Aurinia Pharmaceuticals Account Relationship Matchups

Aurinia Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	326.7M	463.7M	543.4M	470.9M	548.1M	575.5M
Other Current Liab	118K	27.8M	33.8M	37.4M	36.2M	38.0M
Total Current Liabilities	11.3M	32.0M	40.6M	46.1M	77.2M	81.0M
Total Stockholder Equity	273.5M	407.8M	479.1M	405.4M	378.0M	396.9M
Property Plant And Equipment Net	93K	10.3M	9.8M	8.6M	116.6M	122.4M
Net Debt	(306.0M)	(263.9M)	(223.2M)	(86.1M)	48.7M	51.2M
Retained Earnings	(539.8M)	(575.2M)	(756.1M)	(864.3M)	(942.3M)	(895.2M)
Accounts Payable	4.2M	2.6M	3.9M	3.1M	4.3M	3.3M
Non Current Assets Total	11.5M	44.2M	30.0M	28.3M	123.3M	129.4M
Net Receivables	368K	1.0M	15.4M	13.5M	24.1M	25.3M
Common Stock Shares Outstanding	93.0M	118.5M	129.4M	141.9M	143.2M	150.4M
Liabilities And Stockholders Equity	326.7M	463.7M	543.4M	470.9M	548.1M	575.5M
Non Current Liabilities Total	41.9M	23.9M	23.6M	19.3M	92.9M	97.6M
Other Current Assets	8.8M	7.2M	12.5M	14.9M	10.5M	11.0M
Other Stockholder Equity	23.7M	39.4M	59.0M	85.5M	120.8M	66.4M
Total Liab	53.2M	55.9M	64.3M	65.4M	170.1M	178.6M
Property Plant And Equipment Gross	93K	10.3M	9.8M	8.6M	118.5M	124.4M
Total Current Assets	315.1M	419.4M	513.3M	442.5M	424.8M	446.0M
Short Term Debt	6.9M	1.6M	2.1M	1.9M	31.2M	32.8M
Intangible Assets	11.2M	9.3M	8.4M	6.4M	5.0M	7.0M
Cash	306.0M	272.4M	231.9M	94.2M	48.9M	66.4M
Non Currrent Assets Other	209K	247K	11.8M	13.3M	1.5M	2.9M
Cash And Short Term Investments	306.0M	398.3M	466.1M	389.4M	350.5M	368.0M
Other Liab	14.4M	16.3M	16.0M	12.2M	14.0M	7.3M
Net Tangible Assets	289.7M	398.4M	470.7M	399.0M	458.9M	481.8M
Other Assets	209K	5.7M	11.8M	13.3M	15.3M	16.1M
Common Stock Total Equity	504.7M	790.5M	944.3M	1.2B	1.4B	1.4B
Common Stock	790.5M	944.3M	1.2B	1.2B	1.2B	1.3B
Property Plant Equipment	93K	4.8M	9.8M	8.6M	7.7M	8.1M
Capital Surpluse	24.7M	23.7M	39.4M	59.0M	67.9M	71.3M
Non Current Liabilities Other	12.3M	1.6M	16.0M	12.2M	10.9M	8.8M
Net Invested Capital	273.5M	407.8M	479.1M	405.4M	378.0M	349.2M

Currently Active Assets on Macroaxis

ESRT	Empire State Realty
C	Citigroup
C	Citigroup
GOOG	Alphabet Inc Class C
DD	Dupont De Nemours

When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:

How To Invest In Aurinia

Details

Is Aurinia Stock a good investment?

Details

What is Aurinia Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.15)

Revenue Per Share

1.536

Quarterly Revenue Growth

0.243

Return On Assets

(0.02)

Return On Equity

(0.06)

The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aurinia Historical Balance Sheet

Aurinia Pharmaceuticals Inventory

41.69 Million

About Aurinia Balance Sheet Analysis

Aurinia Pharmaceuticals Balance Sheet Chart

Total Current Liabilities

Additional Paid In Capital

Aurinia Pharmaceuticals balance sheet Correlations

Aurinia Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aurinia Pharmaceuticals balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Total Current Assets
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Common Stock Shares Outstanding	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Assets
Cash	- 0.95	Net Debt
Total Current Assets	- 0.94	Retained Earnings
Other Current Assets	- 0.94	Retained Earnings
Inventory	- 0.93	Retained Earnings